Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -4% Improvement Relative Risk Mechanical ventilation or.. 2% Progression 15% c19early.org/s Tsuzuki et al. Remdesivir for COVID-19 LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 12,487 patients in Japan No significant difference in outcomes seen Tsuzuki et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2022.02.039 Favors remdesivir Favors control
Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan
Tsuzuki et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.02.039 (date from earlier preprint)
Tsuzuki et al., Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients in Japan: A large observational study using.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.02.039 (date from earlier preprint)
Mar 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective database analysis of 12,487 hospitalized patients in Japan, showing lower risk of oxygen requirement, but no significant difference in mortality or ventilation/ECMO.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 4.0% higher, HR 1.04, p = 0.21, treatment 69 of 824 (8.4%), control 285 of 11,663 (2.4%), adjusted per study, day 30.
risk of mechanical ventilation or ECMO, 1.7% lower, HR 0.98, p = 0.68, treatment 48 of 824 (5.8%), control 98 of 11,663 (0.8%), adjusted per study.
risk of progression, 15.0% lower, HR 0.85, p = 0.68, treatment 559 of 824 (67.8%), control 1,784 of 11,663 (15.3%), adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tsuzuki et al., 10 Mar 2021, retrospective, Japan, peer-reviewed, 21 authors, average treatment delay 6.0 days.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: Journal Pre-proof Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan Shinya Tsuzuki , Kayoko Hayakawa , Yukari Uemura , Tomohiro Shinozaki , Nobuaki Matsunaga , Mari Terada , Setsuko Suzuki , Yusuke Asai , Koji Kitajima , Sho Saito , Gen Yamada , Taro Shibata , Masashi Kondo , Kazuo Izumi , Masayuki Hojo , Tetsuya Mizoue , Kazuhisa Yokota , Fukumi Nakamura-Uchiyama , Fumitake Saito , Wataru Sugiura , Norio Ohmagari PII: DOI: Reference: S1201-9712(22)00118-7 https://doi.org/10.1016/j.ijid.2022.02.039 IJID 6030 To appear in: International Journal of Infectious Diseases Received date: Revised date: Accepted date: 17 January 2022 15 February 2022 17 February 2022 Please cite this article as: Shinya Tsuzuki , Kayoko Hayakawa , Yukari Uemura , Tomohiro Shinozaki , Nobuaki Matsunaga , Mari Terada , Setsuko Suzuki , Yusuke Asai , Koji Kitajima , Sho Saito , Gen Yamada , Taro Shibata , Masashi Kondo , Kazuo Izumi , Masayuki Hojo , Tetsuya Mizoue , Kazuhisa Yokota , Fukumi Nakamura-Uchiyama , Fumitake Saito , Wataru Sugiura , Norio Ohmagari , Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan, International Journal of Infectious Diseases (2022), doi: https://doi.org/10.1016/j.ijid.2022.02.039 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan Shinya Tsuzukia,b,*, Kayoko Hayakawaa,c, Yukari Uemurad, Tomohiro Shinozakie, Nobuaki Matsunagaa, Mari Teradac,d, Setsuko Suzukic, Yusuke Asaia, Koji Kitajimad, Sho Saitoc, Gen Yamadac, Taro Shibataf, Masashi Kondog, Kazuo Izumid, Masayuki Hojoh, Tetsuya Mizouei, Kazuhisa Yokotaj, Fukumi Nakamura-Uchiyamak, Fumitake Saitol, Wataru Sugiurad, Norio Ohmagaria,c a AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan b c Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan d Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan e Department of Information and Computer Technology, Faculty of Engineering, Tokyo University of Science, Tokyo, Japan f Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan 1 g Center for Clinical Trial and Research Support, Fujita Health University, Aichi, Japan h Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan i Department of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit